Ives Health Company, Inc.
SECURITIES EXCHANGE ACT OF 1934
RELEASE NO. 44038 / March 5, 2001
The Securities and Exchange Commission announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (the "Exchange Act"), of over-the-counter trading of the securities of Ives Health Company, Inc. ("Ives Health") of Claremore, Oklahoma, at 9:30 a.m. on March 5, 2001 and terminating at 11:59 p.m. on March 16, 2001.
The Commission temporarily suspended trading in the securities of Ives Health because of questions regarding the accuracy of public statements by Ives Health to investors concerning, among other things, a product being marketed by Ives Health for treatment of human immunodeficiency virus (HIV).
The Commission cautions brokers-dealers, shareholders, and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by the company.
Further, brokers and dealers should be alert to the fact that, pursuant to rule 15c2-11 under the Exchange Act, at the termination of the trading suspension, no quotation may be entered unless and until they have strictly complied with all of the provisions of the rule. If any broker or dealer has any questions as to whether or not they have complied with the rule, they should not enter any quotation but immediately contact the staff of the Securities and Exchange Commission in Washington, D.C. If any broker or dealer is uncertain as to what is required by Rule 15c2-11, they should refrain from entering quotations relating to Ives Health securities until such time as they have familiarized themselves with the rule and are certain that all of its provisions have been met. If any broker or dealer enters any quotation that is in violation of the rule, the Commission will consider the need for prompt enforcement action.
If any broker-dealer or other person has any information which may relate to this matter, Dorothy Heyl of the Northeast Regional Office of the Securities and Exchange Commission should be telephoned at (212) 748-8213.